From what 15 stock analysts predict, the share price for Sage Therapeutics Inc (SAGE) might increase by 68.26% in the next year. This is based on a 12-month average estimation for SAGE. Price targets go from $4 to $26. The majority of stock analysts believe SAGE is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
SAGE is a stock in Healthcare which has been forecasted to be worth $10.18 as an average. On the higher end, the forecast price is $26 USD by Brian Abrahams from RBC Capital and on the lower end SAGE is forecasted to be $4 by Brian Abrahams from RBC Capital.
These are the latest 20 analyst ratings of SAGE.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Yasmeen Rahimi Piper Sandler | Overweight | $26 | Reiterates | Oct 30, 2024 |
Douglas Tsao HC Wainwright & Co. | Neutral | $14 | Maintains | Oct 30, 2024 |
Joon Lee Truist Securities | Hold | $8 | Maintains | Oct 30, 2024 |
Jay Olson Oppenheimer | Perform | $8 | Maintains | Oct 30, 2024 |
George Farmer Scotiabank | Sector Outperform | $14 | Maintains | Oct 30, 2024 |
Ami Fadia Needham | Hold | Reiterates | Oct 30, 2024 | |
Ami Fadia Needham | Hold | Reiterates | Oct 17, 2024 | |
Danielle Brill Raymond James | Market Perform | Reinstates | Oct 10, 2024 | |
Tazeen Ahmad B of A Securities | Underperform | $6 | Maintains | Oct 9, 2024 |
Joel Beatty Baird | Neutral | $9 | Maintains | Oct 9, 2024 |
Laura Chico Wedbush | Neutral | $8 | Maintains | Oct 9, 2024 |
Douglas Tsao HC Wainwright & Co. | Neutral | $25 | Reiterates | Oct 9, 2024 |
Ami Fadia Needham | Hold | Reiterates | Oct 8, 2024 | |
Brian Abrahams RBC Capital | Underperform | $4 | Downgrade | Oct 4, 2024 |
Joon Lee Truist Securities | Hold | $13 | Maintains | Aug 14, 2024 |
Anupam Rama JP Morgan | Neutral | $10 | Maintains | Aug 6, 2024 |
Douglas Tsao HC Wainwright & Co. | Neutral | $25 | Reiterates | Aug 2, 2024 |
Piper Sandler | Overweight | Maintains | Aug 1, 2024 | |
Ami Fadia Needham | Hold | Reiterates | Aug 1, 2024 | |
Ritu Baral TD Cowen | Hold | $10 | Downgrade | Jul 30, 2024 |
When did it IPO
2014
Staff Count
487
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Barry E. Greene
Market Cap
$371.9M
In 2023, SAGE generated $86.5M in revenue, which was a increase of 1,024.84% from the previous year. This can be seen as a signal that SAGE's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Sage Therapeutics reported Q3 2024 earnings that missed estimates, resulting in a decline in stock price during after-hours trading.
Why It Matters - Earnings misses can signal operational issues or reduced growth potential, leading to decreased investor confidence and stock price declines. This impacts overall market sentiment toward the company.
Summary - Sage Therapeutics will host its Q3 2024 earnings conference call on October 29, 2024, at 4:30 PM ET, featuring key executives including the CEO and CFO.
Why It Matters - Sage Therapeutics' earnings call signals potential updates on financial performance and pipeline progress, influencing stock valuation and investor sentiment.
Summary - A class action lawsuit has been filed against Sage Therapeutics, Inc. (NASDAQ: SAGE) and its officers, as announced by law firm Bronstein, Gewirtz & Grossman, LLC.
Why It Matters - A class action lawsuit against Sage Therapeutics could lead to financial liabilities, regulatory scrutiny, and impact stock performance, prompting investors to reassess their positions.
Summary - A class action lawsuit has been filed against Sage Therapeutics (NASDAQ: SAGE) for securities violations. Investors who bought shares from April 12, 2021, to July 23, 2024, should contact the Schall Law Firm before October 28, 2024.
Why It Matters - The class action lawsuit against Sage Therapeutics may signal potential legal and financial risks, impacting stock performance and investor sentiment regarding the company's future.
Summary - A class action lawsuit has been filed against Sage Therapeutics (NASDAQ:SAGE) for alleged violations of federal securities laws during the period from April 12, 2021, to July 23, 2024.
Why It Matters - A class action lawsuit against Sage Therapeutics may lead to financial liabilities and reputational damage, impacting stock performance and investor sentiment.
Summary - Sage Therapeutics, Inc. (NASDAQ:SAGE) investors who suffered losses may explore potential recovery under federal securities laws. More info is available via the provided link or by contacting legal counsel.
Why It Matters - The news indicates potential legal action against Sage Therapeutics, which may affect the company's stock price and investor sentiment, highlighting risks in ongoing investments.